Aequus Pharmaceuticals (TSE:AQS) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Aequus Pharmaceuticals Inc. has seen a positive second quarter in 2024 with a notable increase in revenue and a reduction in net losses compared to the previous year. The company reported a 12% rise in revenue and a decrease in net losses by 2.55% for the quarter, attributing this improvement to greater sales of ZIMED® PF and effective cost-cutting measures.
For further insights into TSE:AQS stock, check out TipRanks’ Stock Analysis page.